Renal Cancer - Results from #2260

Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival. January 13, 2021

Circ_101341 Deteriorates the Progression of Clear Cell Renal Cell Carcinoma Through the miR- 411/EGLN3 Axis. January 12, 2021

Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study. January 12, 2021

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports. January 11, 2021

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. January 11, 2021

Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. January 11, 2021

Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma. January 8, 2021

New Baseline Renal Function after Radical or Partial Nephrectomy: A Simple and Accurate Predictive Model. January 8, 2021

Dysregulation of Long Non-coding RNAs and mRNAs in Plasma of Clear Cell Renal Cell Carcinoma Patients Using Microarray and Bioinformatic Analysis. January 8, 2021

Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry. January 7, 2021

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. January 7, 2021

MicroRNAs MiR-15a and MiR-26a cooperatively regulate O-GlcNAc-transferase to control proliferation in clear cell renal cell carcinoma. January 7, 2021

Factors Affecting Long Term Renal Functions after Partial versus Radical Nephrectomy for Clinical T1 Renal Masses: A Multicenter Study of the Urooncology Association, Turkey. January 6, 2021

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma. January 6, 2021

Percutaneous thermoablation of small renal masses (T1a) in surgical candidate patients: oncologic outcomes. January 6, 2021

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma. January 5, 2021

Percutaneous Cryoablation versus Robot-Assisted Partial Nephrectomy of Renal T1A Tumors: a Single-Center Retrospective Cost-Effectiveness Analysis. January 5, 2021

Parenchymal biopsy in the management of patients with renal cancer. January 5, 2021

Preoperative prediction of the stage, size, grade, and necrosis score in clear cell renal cell carcinoma using MRI-based radiomics. January 4, 2021

Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma. January 4, 2021

Page 114 of 456